Skip to main content

Advertisement

SpringerLink
Log in

Treatment of Concomitant OAB and BPH

  • Female Urology (K Kobashi, Section Editor)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

The etiology of men’s lower urinary tract storage and voiding symptoms involves a contribution from both detrusor and outlet. As such, treatment of benign prostatic enlargement (BPE) ± benign prostatic obstruction (BPO) with standard alpha-adrenergic blockade and 5-alpha reductase inhibitor therapy may leave a population of men with persistent and bothersome urinary storage symptoms. An abundance of adequately powered, randomized, placebo-controlled trials indicate that the use of antimuscarinics and beta-3 adrenergic agonists, either alone or in combination with standard BPE/BPO therapy, leads to improvement in storage symptoms. At the same time, metrics associated with urinary emptying, such as maximum flow rate, post-void residual urinary volume, and incidence of treatment-associated urinary retention, appear to be stable and not significantly impacted by the addition of antimuscarinics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Abrams P, Cardozo L, Fall M, et al. The standardization of terminology in lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Urology. 2003;61:37–49.

    Article  PubMed  Google Scholar 

  2. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44:637–49.

    Article  PubMed  Google Scholar 

  3. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–14.

    Article  PubMed  Google Scholar 

  4. Witjes WP, de la Rosette JJ, Donovan JL, et al. The International Continence Society “Benign Prostatic Hyperplasia” Study: international differences in lower urinary tract symptoms and related bother. J Urol. 1997;157:1295–300.

    Article  CAS  PubMed  Google Scholar 

  5. Hyman MJ, Groutz A, Blaivas JG. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol. 2001;166:550–3.

    Article  CAS  PubMed  Google Scholar 

  6. Kaplan SA, Ikeguchi EF, Santarosa RP, et al. Etiology of voiding dysfunction in men less than 50 years of age. Urology. 1996;47:836–9.

    Article  CAS  PubMed  Google Scholar 

  7. Abrams P, Andersson KE, Birder L, Members of Committees, Fourth International Consultation on Incontinence, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29:213–40.

    Article  CAS  PubMed  Google Scholar 

  8. Roehrborn CG. Chapter 103: Benign Prostatic Hyperplasia: Etiology, Pathophysiology, Epidemiology, and Natural History. In: Campbell and Walsh Urology, 11th Edition; Wein AJ, Kavoussi LR, Partin AW, Peters CA (Eds), Elsevier-Saunders, Philadephia, PA. p. 2435.

  9. Levin RM, Monson FC, Haugaard N, et al. Genetic and cellular characteristics of bladder outlet obstruction. Urol Clin North Am. 1995;22:263–83.

    CAS  PubMed  Google Scholar 

  10. Levin RM, Haugaard N, O’Connor L, et al. Obstructive response of human bladder to BPH vs. rabbit bladder response to partial outlet obstruction: a direct comparison. Neurourol Urodyn. 2000;19:609–29.

    Article  CAS  PubMed  Google Scholar 

  11. Gosling JA, Gilpin SA, Dixon JS, et al. Decrease in the autonomic innervation of human detrusor muscle in outflow obstruction. J Urol. 1986;136:501–4.

    CAS  PubMed  Google Scholar 

  12. Nordling J. The aging bladder—a significant but underestimated role in the development of lower urinary tract symptoms. Exp Gerontol. 2002;37:991–9.

    Article  PubMed  Google Scholar 

  13. Chai TC, Andersson KE, Tuttle JB, et al. Altered neural control of micturition in the aged f344 rat. Urol Res. 2000;28:348–54.

    Article  CAS  PubMed  Google Scholar 

  14. Abrams PH, Farrar DJ, Turner-Warwick RT, et al. The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J Urol. 1979;121:640–2.

    CAS  PubMed  Google Scholar 

  15. Van Venrooj GE, Van Melick HH, Eckhardt MD, et al. Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate. J Urol. 2002;168:605–9.

    Article  Google Scholar 

  16. • McConnell JD, Roehrborn CG, Bautista OM, et al. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387–98. Large RCT showing that AUASS was significantly greater in the group treated with finasteride and doxazosin combination-therapy than in the finasteride doxazosin monotherapy groups.

    Article  CAS  PubMed  Google Scholar 

  17. Kaplan SA, Roehrborn CG, Dmochowski R, et al. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology. 2006;68:328–32.

    Article  PubMed  Google Scholar 

  18. Dmochowski R, Abrams P, Marschall-Kehrel D, Wang JT, Guan Z. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol. 2007;51:1054–64.

    Article  CAS  PubMed  Google Scholar 

  19. Roehrborn CG, Abrams P, Rovner ES, et al. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int. 2006;97:1003–6.

    Article  CAS  PubMed  Google Scholar 

  20. Herschorn S, Jones JS, Oelke M, et al. Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies. Urology. 2010;75:1149–55.

    Article  PubMed  Google Scholar 

  21. Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol. 2006;175:999–1004.

    Article  CAS  PubMed  Google Scholar 

  22. Gacci M, Novara G, De Nunzio C, et al. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review. BMC Urol. 2014;14:84.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Buser N, Ivic S, Kessler T, Kessels A, Bachmann L. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol. 2012;62:1040–60.

    Article  CAS  PubMed  Google Scholar 

  24. Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189:1388–95.

    Article  CAS  PubMed  Google Scholar 

  25. Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63:283–95.

    Article  CAS  PubMed  Google Scholar 

  26. Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82:313–20.

    Article  PubMed  Google Scholar 

  27. • Nitti VW, Khullar V, van Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013;67:619–32. Pooled efficacy and safety analysis of mirabegron for OAB.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Chapple CR, Kaplan SA, Mitcheson D, et al. Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year. Int J Urol. 2014;21:960–7.

    Article  CAS  PubMed  Google Scholar 

  29. Nitti VW, Rosenberg S, Mitcheson DH, et al. Urodynamics and safety of the β3-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013;190:1320–7.

    Article  CAS  PubMed  Google Scholar 

  30. Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003;169:2253–6.

    Article  CAS  PubMed  Google Scholar 

  31. Lee JY, Kim HW, Lee SJ, et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int. 2004;94:817–20.

    Article  CAS  PubMed  Google Scholar 

  32. Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol. 2005;174:2273–6.

    Article  PubMed  Google Scholar 

  33. Yang Y, Zhao XF, Li HZ, et al. Efficacy and safety of combined therapy with terazosin and tolterodine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Chin Med J (Engl). 2007;120:370–4.

    CAS  Google Scholar 

  34. Kaplan SA, Roehrborn CG, Gong J, Sun F, Guan Z. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms. BJU Int. 2012;109:1831–40.

    Article  CAS  PubMed  Google Scholar 

  35. Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol. 2009;182:2825–30.

    Article  PubMed  Google Scholar 

  36. Chapple C, Herschorn S, Abrams P, et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol. 2009;56:534–41.

    Article  CAS  PubMed  Google Scholar 

  37. Lee SH, Chung BH, Kim SJ, et al. Initial combined treatment with anticholinergics and alpha-blockers for men with lower urinary tract symptoms related to BH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer Prostatic Dis. 2011;14:320–5.

    Article  CAS  PubMed  Google Scholar 

  38. Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. JAMA. 2006;296:2319–28.

    Article  CAS  PubMed  Google Scholar 

  39. Kaplan SA, Roehrborn CG, Chancellor M, et al. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU Int. 2008;102:1133–9.

    Article  CAS  PubMed  Google Scholar 

  40. MacDiarmid SA, Peters KM, Chen A, et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc. 2008;83:1002–10.

    Article  CAS  PubMed  Google Scholar 

  41. Kim TH, Jung W, Suh YS, et al. Comparison of the efficacy and safety of tolterodine 2 mg and 4 mg combined with an alpha-blocker in men with lower urinary tract symptoms (LUTS) and overactive bladder: a randomized controlled trial. BJU Int. 2016;117:307–15.

    Article  CAS  PubMed  Google Scholar 

  42. Singh I, Agarwal V, Garg G. ‘Tamsulosin and Darifenacin’ Versus ‘Tamsulosin Monotherapy’ for ‘BPH with Accompanying Overactive Bladder’. J Clin Diagn Res. 2015;9:PC08-11.

    PubMed  Google Scholar 

  43. Yamaguchi O, Kakizaki H, Homma Y, ASSIST Study Group, et al. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms—ASSIST, randomized controlled study. Urology. 2011;78:126–33.

    Article  PubMed  Google Scholar 

  44. van Kerrebroeck P, Chapple C, Drogendijk T, et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013;64:1003–12.

    Article  PubMed  Google Scholar 

  45. •• Drake MJ, Chapple C, Sokol R, et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE study and NEPTUNE II open-label extension. Eur Urol. 2015;67:262–70. Long-term treatment with α-blocker and antimuscarinic agent was associated with a low incidence of urinary retention. Symptomatic improvement seen at four weeks was maintained for up to one year.

    Article  CAS  PubMed  Google Scholar 

  46. Kosilov KV, Loparev SA, Ivanovskaya MA, Kosilova LV. Effectiveness of solifenacin and trospium for managing of severe symptoms of overactive bladder in patients with benign prostatic hyperplasia. Am J Mens Health. 2016;10:157–63.

    Article  PubMed  Google Scholar 

  47. • Ichihara K, Masumori N, Fukuta F, et al. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. J Urol. 2015;193:921–6. First RCT demonstrating the efficacy of combination therapy using an α-blocker and β-3 adrenoceptor agonist for men with BPO and OAB.

    Article  CAS  PubMed  Google Scholar 

  48. Chung DE, Te AE, Staskin DR, Kaplan SA. Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams. Urology. 2010;75:1144–8.

    Article  PubMed  Google Scholar 

  49. Filson CP, Hollingsworth JM, Clemens JQ, Wei JT. The efficacy and safety of combined therapy with α-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis. J Urol. 2013;190:2153–60.

    Article  CAS  PubMed  Google Scholar 

  50. Hao N, Tian Y, Liu W, et al. Antimuscarinics and α-blockers or α-blockers monotherapy on lower urinary tract symptoms—a meta-analysis. Urology. 2014;83:556–62.

    Article  PubMed  Google Scholar 

  51. Gong M, Dong W, Huang G, et al. Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis. Curr Med Res Opin. 2015;31:1781–92.

    Article  CAS  PubMed  Google Scholar 

  52. Rosenberg MT, Staskin DR, Kaplan SA, et al. A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting. Int J Clin Pract. 2007;61:1535–46.

    Article  CAS  PubMed  Google Scholar 

  53. • Oelke M, Becher K, Castro-Diaz D, et al. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing. 2015;44:745–55. Review suggesting that drug therapy (and especially combination therapy) may be concerning in the elderly.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Louisiana State University Health - Shreveport, 1501 Kings Highway, Shreveport, LA, 71130, USA

    Matthew C. Moss, Tameem Rezan, Umar R. Karaman & Alex Gomelsky

Authors
  1. Matthew C. Moss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tameem Rezan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Umar R. Karaman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alex Gomelsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alex Gomelsky.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Female Urology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moss, M.C., Rezan, T., Karaman, U.R. et al. Treatment of Concomitant OAB and BPH. Curr Urol Rep 18, 1 (2017). https://doi.org/10.1007/s11934-017-0649-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11934-017-0649-z

Keywords

Search

Navigation